Robert A. Lenz - 18 Feb 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Signature
/s/ Michael Milligan, as Attorney-in-Fact for Robert A. Lenz
Issuer symbol
NMRA
Transactions as of
18 Feb 2025
Net transactions value
-$9,383
Form type
4
Filing time
20 Feb 2025, 17:12:34 UTC
Previous filing
18 Feb 2025
Next filing
10 Mar 2026

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NMRA Common Stock Sale $9,383 -5,614 -1.8% $1.67 309,092 18 Feb 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
F2 This transaction was executed in multiple trades in prices ranging from $1.66 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.